Jin-Sung Lee

Jin-Sung Lee

Auto-generated profile, based on publicly available information

Jin-Sung Lee

Division of Clinical Genetics, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2002 in Cell Transplantation
Verified
Journal Article
Open access
DCDongho Choi
Dongho Choi
HOHyun-Jeong Oh
Hyun-Jeong Oh
UCUck-Jin Chang
Uck-Jin Chang
SKSoo Kyung Koo
Soo Kyung Koo
Jean X. JiangJean X. Jiang
Jean X. Jiang
BOBermseok Oh
Bermseok Oh
Embryonic stem (ES) cells have been regarded as a powerful resource for cell replacement therapy. In recent reports mouse ES cells have been successfully applied in the treatment of spinal cord injury, hereditary myelin disorder of the central nervous system, and diabetes mellitus. Another type of disease that could benefit from the availability of stem cell therapy is liver disease. However, for this potential to be realized, it is necessary to demonstrate the differentiation of ES cells into hepatocytes. To demonstrate the in vivo differentiation potential of mouse ES cells, we injected ES cells into the spleen of immunosuppressed nude mice. Histological analysis of teratomas derived from injected ES cells revealed that some areas contained typical hepatocytes arranged in a sinusoidal structure. The hepatic nature of these cells was further confirmed by showing that transcripts of liver-specific genes were present in the differentiated teratoma using reverse transcriptase-polymerase chain reaction and immunohistochemistry using several liver-specific antibodies including HEP-PAR, phenylalanine hydroxylase, and mouse N-system aminotransferase to identify the respective proteins in the differentiated hepatocytes. This is the first demonstration that mouse ES cells can differentiate in vivo into a mixed population of hepatocytes of varying maturity. This finding extends the potential use of ES cells in the cell replacement therapy by including its possible application for treating liver diseases.

19 December 2016 in Scientific Reports
Verified
Journal Article
Open access
YKYounhee Ko
Younhee Ko
MCMinah Cho
Minah Cho
JLJin-Sung Lee
Jin-Sung Lee
JKJaebum Kim
Jaebum Kim
Despite multiple diseases co-occur, their underlying common molecular mechanisms remain elusive. Identification of comorbid diseases by considering the interactions between molecular components is a key to understand the underlying disease mechanisms. Here, we developed a novel approach utilizing both common disease-causing genes and underlying molecular pathways to identify comorbid diseases. Our approach enables the analysis of common pathologies shared by comorbid diseases through molecular interaction networks. We found that the integration of direct genetic sharing and indirect high-level molecular associations revealed significantly strong consistency with known comorbid diseases. In addition, neoplasm-related diseases showed high comorbidity patterns within themselves as well as with other diseases, indicating severe complications. This study demonstrated that molecular pathway information could be used to discover disease comorbidity and hidden biological mechanism to understand pathogenesis and provide new insight on disease pathology.

1 February 2015 in Journal of Chromatography A
Verified
Journal Article
Closed access
SBSeul Kee Byeon
Seul Kee Byeon
JLJu Yong Lee
Ju Yong Lee
JLJin-Sung Lee
Jin-Sung Lee
MMMyeong Hee Moon
Myeong Hee Moon

1 January 2010 in Korean Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
HPHyun Bin Park
Hyun Bin Park
SLSoon Min Lee
Soon Min Lee
JLJin Sung Lee
Jin Sung Lee
MPMin Soo Park
Min Soo Park
KPKook In Park
Kook In Park
CLChul Lee
Chul Lee
The life expectancy of patients with spinal muscular atrophy (SMA) type I is generally considered to be less than 2 years. Recently, with the introduction of proactive treatments, a longer survival and an improved survival rate have been reported. In this study, we analyzed the natural courses and survival statistics of SMA type I patients and compared the clinical characteristics of the patients based on their survival periods. We reviewed the medical records of 14 pediatric patients diagnosed with SMA type I during a 9-year period. We examined the demographic and clinical characteristics of these patients, calculated their survival probabilities, and plotted survival curves as on the censoring date, January 1, 2010. We also compared the characteristics of the patients who died before the age of 24 months (early-death, ED group) and those who survived for 24 months or longer (long-survival, LS group). The mean survival time was 22.8±2.0 months. The survival probabilities at 6 months, 12 months, 18 months, 24 months, and 30 months were 92.9%, 92.9%, 76.0%, 76.0%, and 65.1%, respectively. Birth weight was the only factor that showed a statistically significant difference between the ED and LS groups (P=0.048). In this study, the survival probabilities at 2 years were far greater than expected. Because of the limited number of patients and information in this study, the contribution of improved supportive care on longer survival could not be clarified; this may be elucidated in larger cohort studies.

29 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YCYangrae Cho
Yangrae Cho
CLChul-Ho Lee
Chul-Ho Lee
EJEun-Goo Jeong
Eun-Goo Jeong
MKMin-Ho Kim
Min-Ho Kim
JHJong Hui Hong
Jong Hui Hong
JLJin-Sung Lee
Jin-Sung Lee
Next-generation sequencing (NGS) technology has improved enough to discover mutations associated with genetic diseases. Our study evaluated the feasibility of targeted NGS as a primary screening tool to detect causal variants and subsequently predict genetic diseases. We performed parallel computations on 3.7-megabase-targeted regions to detect disease-causing mutations in 103 participants consisting of 81 patients and 22 controls. Data analysis of the participants took about 6 hours using local databases and 200 nodes of a supercomputer. All variants in the selected genes led on average to 3.6 putative diseases for each patient while variants restricted to disease-causing genes identified the correct disease. Notably, only 12% of predicted causal variants were recorded as causal mutations in public databases: 88% had no or insufficient records. In this study, most genetic diseases were caused by rare mutations and public records were inadequate. Most rare variants, however, were not associated with genetic diseases. These data implied that novel, rare variants should not be ignored but interpreted in conjunction with additional clinical data. This step is needed so appropriate advice can be given to primary doctors and parents, thus fulfilling the purpose of this method as a primary screen for rare genetic diseases.

31 July 2014 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
SHSena Hwang
Sena Hwang
Cheol Ryong KuCheol Ryong Ku
Cheol Ryong Ku
JLJi In Lee
Ji In Lee
KHKyu Yeon Hur
Kyu Yeon Hur
MLMyung-Shik Lee
Myung-Shik Lee
YRYumie Rhee
Yumie Rhee